The O
Efficacy O
and O
Safety O
of O
Modified O
Docetaxel B-DESC
, O
Cisplatin B-DESC
, O
and O
5-Fluorouracil B-DESC
Vs O
. O
Epirubicin B-DESC
, O
Oxaliplatin B-DESC
, O
and O
Capecitabine B-DESC
Regimen O
in O
the O
Advanced O
Gastric O
Cancer O
: O
A O
Randomized B-STYPE
Controlled I-STYPE
Clinical I-STYPE
Trial I-STYPE
The O
Efficacy O
and O
Safety O
of O
Modified O
Docetaxel O
, O
Cisplatin O
, O
and O
5-Fluorouracil O
Vs O
. O
Epirubicin B-DESC
, O
Oxaliplatin B-DESC
, O
and O
Capecitabine B-DESC
Regimen O
in O
the O
Advanced O
Gastric O
Cancer O
: O
A O
Randomized B-STYPE
Controlled I-STYPE
Clinical I-STYPE
Trial I-STYPE
AhmadAhmadzadeh B-AUTH

The O
Efficacy O
and O
Safety O
of O
Modified O
Docetaxel B-DESC
, O
Cisplatin B-DESC
, O
and O
5-Fluorouracil B-DESC
Vs O
. O
Epirubicin B-DESC
, O
Oxaliplatin B-DESC
, O
and O
Capecitabine B-DESC
Regimen O
in O
the O
Advanced O
Gastric O
Cancer O
: O
A O
Randomized B-STYPE
Controlled I-STYPE
Clinical I-STYPE
Trial I-STYPE

The O
Efficacy O
and O
Safety O
of O
Modified O
Docetaxel B-DESC
, O
Cisplatin B-DESC
, O
and O
5-Fluorouracil B-DESC
Vs O
. O
Epirubicin B-DESC
, O
Oxaliplatin B-DESC
, O
and O
Capecitabine B-DESC
Regimen O
in O
the O
Advanced O
Gastric O
Cancer O
: O
A O
Randomized B-STYPE
Controlled I-STYPE
Clinical I-STYPE
Trial I-STYPE
AhmadAhmadzadeh B-AUTH

Student O
Research O
Committee O
HosseinHamidi B-AUTH
Hossein I-AUTH
Hamidi I-AUTH
Student O
Research O
Committee O
Student O
Research O
Committee O
The O
Efficacy O
and O
Safety O
of O
Modified O
Docetaxel B-DESC
, O
Cisplatin B-DESC
, O
and O
5-Fluorouracil B-DESC
Vs O
. O
Epirubicin B-DESC
, O
Oxaliplatin B-DESC
, O
and O
Capecitabine B-DESC
Regimen O
in O
the O
Advanced O
Gastric O
Cancer O
: O
A O
Randomized B-STYPE
Controlled I-STYPE
Clinical I-STYPE
Trial I-STYPE
10.31557 O
/ O
APJCP.2020.21.3.727 O

Despite O
all O
advances O
in O
the O
prevention O
, O
diagnosis O
, O
and O
treatment O
of O
gastric O
cancer O
, O
one O
million O
new O
cases O
were O
diagnosed O
in O
2018 O
, O
and O
783,000 O
people O
died O
because O
of O
the O
disease O
. O
Considering O
the O
serious O
consequences O
of O
gastric O
cancer O
, O
it O
can O
alone O
undermine O
all O
advances O
made O
in O
this O
area O
( O
Bray O
et O
al O
. O
, O
2018 O
) O
. O
Since O
the O
disease O
continues O
to O
be O
asymptomatic O
until O
advanced O
stages O
, O
the O
main O
treatment O
options O
are O
practically O
limited O
to O
palliative O
three O
- O
drug O
chemotherapy O
regimens O
( O
Nishiyama O
and O
Wada O
, O
2009;Van O
et O
al O
. O
, O
2011;Kuo O
et O
al O
. O
, O
2014 O
) O
. O

Although O
different O
studies O
have O
been O
conducted O
on O
the O
efficacy O
, O
safety O
, O
and O
tolerability O
of O
m O
- O
DCF O
and O
EOX O
regimens O
, O
few O
studies O
have O
compared O
these O
two O
regimens O
. O
Therefore O
, O
we O
designed O
and O
performed O
this O
trial O
to O
determine O
the O
optimal O
chemotherapy O
regimen O
for O
patients O
with O
stage O
IV O
gastric O
cancer O
. O

This O
study O
was O
a O
randomized B-STYPE
clinical I-STYPE
trial I-STYPE
conducted O
between O
2016 O
and O
2019 O
in O
the O
Oncology O
Department O
of O
Shafa O
Hospital O
, O
as O
the O
largest O
tertiary O
referral O
center O
of O
oncology O
in O
southwest O
of O
Iran O
. O
The O
participants O
were O
patients O
with O
advanced O
( O
inoperable O
) O
or O
metastatic O
gastric O
adenocarcinoma O
, O
whose O
diseases O
were O
confirmed O
by O
histological O
studies O
. O

Advanced O
gastric O
cancer O
patients O
, O
aged O
18 O
to O
65 O
years O
with O
an O
Eastern O
Cooperative O
Oncology O
Group O
( O
ECOG O
) O
status O
≤ O
1 O
, O
adequate O
cardiac O
, O
pulmonary O
, O
and O
renal O
function O
, O
and O
lack O
of O
specific O
psychological O
, O
familial O
, O
social O
, O
and O
geographical O
situations O
that O
may O
affect O
compliance O
and O
adherence O
to O
treatment O
, O
were O
included O
. O
Patients O
with O
sensory O
peripheral O
neuropathy O
≥ O
grade O
1 O
( O
according O
to O
CTCAE O
version O
3.0 O
) O
, O
myocardial O
infarction O
, O
unstable O
angina O
for O
less O
than O
six O
months O
before O
the O
start O
of O
the O
study O
, O
stroke O
or O
pulmonary O
embolism O
, O
uncontrolled O
infection O
, O
pregnancy O
or O
lactation O
, O
and O
history O
of O
other O
malignancies O
and O
chemotherapy O
were O
excluded O
. O

Before O
the O
beginning O
of O
the O
study O
, O
the O
trial O
was O
first O
approved O
by O
the O
ethics O
committee O
of O
Ahvaz O
Jundishapur O
University O
of O
Medical O
Sciences O
with O
the O
Ethics O
Committee O
reference O
number O
, O
Ir.ajums.rec.1395.763 O
. O
The O
trial O
was O
also O
registered O
in O
the O
Iranian O
Registry O
of O
Clinical O
Trials O
( O
IRCT2017062134670N1 O
) O
at O
07/08/2017 O
. O
In O
addition O
, O
voluntary O
informed O
consent O
was O
obtained O
from O
all O
patients O
according O
to O
the O
Declaration O
of O
Helsinki O
. O

Eligible O
subjects O
were O
randomly O
divided O
into O
two O
groups O
by O
block O
randomization O
method O
, O
and O
finally O
, O
21 O
patients O
in O
the O
m O
- O
DCF B-DESC
arm I-DESC
and O
19 O
patients O
in O
the O
EOX B-DESC
arm I-DESC
were O
enrolled O
. O
The O
investigator O
responsible O
for O
randomization O
was O
not O
involved O
in O
the O
assessment O
of O
efficacy O
and O
safety O
of O
regimens O
. O
Assessments O
before O
the O
start O
of O
treatment O
included O
history O
- O
taking O
, O
physical O
examination O
, O
complete O
blood O
cell O
count O
( O
CBC O
) O
, O
coagulation O
tests O
( O
PT O
and O
PTT O
) O
, O
and O
serum O
biochemistry O
and O
liver O
function O
tests O
( O
LFT O
) O
. O
One O
month O
before O
the O
intervention O
, O
chest O
and O
abdominopelvic O
CT O
scans O
( O
with O
or O
without O
upper O
gastrointestinal O
tract O
endoscopy O
) O
were O
performed O
. O

The O
first O
group O
received O
the O
m B-DESC
- I-DESC
DCF I-DESC
regimen O
as O
follows O
: O
docetaxel B-DESC
( O
40 B-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
; O
Sanofi O
, O
France O
) O
, O
diluted B-DOSAGE
in I-DOSAGE
500 I-DOSAGE
mL I-DOSAGE
of I-DOSAGE
normal I-DOSAGE
saline I-DOSAGE
and O
infused O
intravenously O
over O
60 O
minutes O
on B-DOSAGE
the I-DOSAGE
first I-DOSAGE
day I-DOSAGE
; O
cisplatin B-DESC
( O
40 B-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
; O
Mylan O
, O
France O
) O
, O
diluted B-DOSAGE
in I-DOSAGE
1,000 I-DOSAGE
mL I-DOSAGE
of I-DOSAGE
normal I-DOSAGE
saline I-DOSAGE
on I-DOSAGE
the I-DOSAGE
first I-DOSAGE
and I-DOSAGE
second I-DOSAGE
days I-DOSAGE
and O
infused O
intravenously O
over O
60 O
minutes O
; O
and O
5-fluorouracil B-DESC
( O
400 B-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
; O
Ebewe O
, O
Australia O
) O
, O
administered O
via O
central O
venous O
catheters O
from O
the O
first B-DOSAGE
to I-DOSAGE
fourth I-DOSAGE
day I-DOSAGE
. O

For O
the O
second O
group O
, O
the O
EOX B-DESC
regimen I-DESC
was O
administered O
as O
follows O
: O
epirubicin B-DESC
( O
50 B-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
; O
Ebew O
, O
Austria O
) O
as O
intravenous O
bolus O
on B-DOSAGE
the I-DOSAGE
first I-DOSAGE
day I-DOSAGE
; O
oxaliplatin B-DESC
( O
130 B-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
; O
Sanofi O
, O
France O
) O
, O
infused O
over O
two O
hours O
on B-DOSAGE
the I-DOSAGE
first I-DOSAGE
day I-DOSAGE
; O
and O
capecitabine B-DESC
( O
625 B-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
; O
Roche O
, O
Switzerland O
) O
on B-DOSAGE
21 I-DOSAGE
days I-DOSAGE
p.o O
. O
For O
both O
regimens O
, O
common O
treatments O
to O
prevent O
nausea O
and O
vomiting O
were O
applied O
. O

The O
treatment O
cycle O
for O
both O
m B-DESC
- I-DESC
DCF I-DESC
and O
EOX B-DESC
treatment I-DESC
regimens O
was O
repeated O
every O
three O
weeks O
for O
a O
maximum O
of O
eight O
cycles O
, O
except O
for O
samples O
with O
disease O
progression O
, O
unacceptable O
toxicity O
, O
withdrawal O
from O
the O
study O
, O
or O
death O
. O
Researchers O
graded O
all O
side O
effects O
and O
toxic O
effects O
in O
patients O
according O
to O
the O
criteria O
of O
the O
National O
Cancer O
Institute O
( O
version O
2.0 O
) O
in O
each O
visit O
. O

After O
completing O
the O
treatment O
, O
the O
patients O
were O
followed O
- O
up O
within O
three O
- O
month O
intervals O
for O
two O
years O
. O
Disease O
progression O
was O
assessed O
using O
physical O
examinations O
, O
carbohydrate O
antigen O
19 O
- O
9 O
( O
CA O
19 O
- O
9 O
) O
and O
carcinoembryonic O
antigen O
tests O
, O
chest O
radiography O
, O
abdominal O
ultrasonography O
, O
and O
, O
if O
necessary O
, O
abdominopelvic O
CT O
scan O
or O
MRI O
. O

Demographic O
data O
and O
other O
continuous O
variables O
are O
reported O
as O
mean±standard O
deviation O
, O
median O
, O
and O
range O
. O
Progression B-METRIC
- I-METRIC
free I-METRIC
survival I-METRIC
( O
PFS B-METRIC
) O
was O
defined O
as O
the O
length O
of O
time O
from O
entering O
the O
study O
until O
the O
first O
report O
of O
relapse O
or O
the O
latest O
follow O
- O
up O
. O
Also O
, O
overall O
survival O
( O
OS O
) O
was O
defined O
as O
the O
length O
of O
time O
from O
the O
onset O
of O
chemotherapy O
to O
death O
or O
the O
latest O
follow O
- O
up O
. O
OS O
and O
PFS B-METRIC
were O
calculated O
by O
Kaplan O
- O
Meier O
method O
and O
compared O
between O
the O
two O
groups O
, O
based O
on O
log O
- O
rank O
test O
. O
P O
- O
value O
less O
than O
0.05 O
was O
considered O
significant O
. O
Data O
analysis O
was O
performed O
in O
SPSS O
version O
14 O
. O

In O
this O
study O
, O
62 O
patients O
with O
gastric O
cancer O
were O
15.00 O
( O
95 O
% O
CI O
: O
9.56 O
- O
20.43 O
) O
months O
, O
respectively O
; O
however O
, O
the O
difference O
was O
not O
statistically O
significant O
between O
the O
groups O
. O
Also O
, O
the O
two O
- O
year O
survival O
rate O
in O
the O
EOX B-DESC
group I-DESC
was O
higher O
than O
that O
of O
the O
m O
- O
DCF O
group O
, O
although O
the O
difference O
was O
not O
statistically O
significant O
( O
P O
> O
0.05 O
) O
( O
Figure O
2 O
) O
. O
In O
addition O
, O
the O
median B-METRIC
PFS I-METRIC
was O
7.00 B-RESULTS
( I-RESULTS
95 I-RESULTS
% I-RESULTS
CI I-RESULTS
: I-RESULTS
2.42 I-RESULTS
- I-RESULTS
11.58 I-RESULTS
) I-RESULTS
months I-RESULTS
in O
the O
m B-DESC
- I-DESC
DCF I-DESC
group I-DESC
and O
8.00 B-RESULTS
( I-RESULTS
95 I-RESULTS
% I-RESULTS
CI I-RESULTS
: I-RESULTS
3.97 I-RESULTS
- I-RESULTS
12.03 I-RESULTS
) I-RESULTS
months I-RESULTS
in O
the O
EOX B-DESC
group I-DESC
( O
Figure O
3 O
) O
; O
however O
, O
there O
was O
no O
significant O
difference O
between O
the O
two O
groups O
( B-RESULTS
P I-RESULTS
> I-RESULTS
0.05 I-RESULTS
) I-RESULTS
. O
Finally O
, O
80.95 O
% O
of O
patients O
from O
the O
m B-DESC
- I-DESC
DCF I-DESC
group I-DESC
and O
73.68 O
% O
of O
patients O
from O
the O
EOX B-DESC
group I-DESC
died O
. O

In O
this O
study O
, O
four O
( O
21.05 O
% O
) O
patients O
from O
the O
EOX B-DESC
group I-DESC
and O
five O
( O
23.80 O
% O
) O
patients O
from O
the O
m B-DESC
- I-DESC
DCF I-DESC
group I-DESC
had O
a O
reduction O
in O
at O
least O
one O
dose O
of O
chemotherapy O
. O
Also O
, O
six O
( O
31.58 O
% O
) O
patients O
from O
the O
EOX B-DESC
group I-DESC
and O
five O
assessed O
for O
eligibility O
criteria O
. O
Forty O
- O
five O
patients O
met O
the O
inclusion O
criteria O
and O
were O
divided O
into O
the O
m B-DESC
- I-DESC
DCF I-DESC
( O
n=21 O
) O
and O
EOX B-DESC
( O
n=19 O
) O
groups O
( O
Figure O
1 O
) O
. O
Twenty O
- O
five O
( O
62.5 O
% O
) O
patients O
were O
male O
, O
while O
the O
rest O
were O
female O
. O
The O
mean O
age O
of O
the O
participants O
was O
58.26±15.39 O
years O
. O
Both O
treatment O
groups O
were O
almost O
homogeneous O
in O
terms O
of O
the O
baseline O
characteristics O
, O
except O
for O
the O
mean O
age O
( O
P= O
0.08 O
) O
and O
liver O
metastasis O
( O
P= O
0.06 O
) O
; O
however O
, O
the O
differences O
were O
not O
significant O
. O
The O
baseline O
characteristics O
of O
the O
patients O
are O
presented O
in O
Table O
1 O
. O

As O
shown O
in O
Table O
2 O
, O
the O
median O
survival O
in O
the O
m B-DESC
- I-DESC
DCF I-DESC
and O
EOX B-DESC
groups I-DESC
was O
14.00 B-RESULTS
( I-RESULTS
95 I-RESULTS
% I-RESULTS
CI I-RESULTS
: I-RESULTS
11.82 I-RESULTS
- I-RESULTS
16.18 I-RESULTS
) I-RESULTS
and I-RESULTS
( I-RESULTS
23.80 I-RESULTS
% I-RESULTS
) I-RESULTS
patients O
from O
the O
m B-DESC
- I-DESC
DCF I-DESC
group O
experienced O
delays O
in O
at O
least O
one O
treatment O
cycle O
due O
to O
toxicity O
induced O
by O
chemotherapy O
; O
however O
, O
the O
two O
groups O
showed O
no O
significant O
difference O
( B-RESULTS
P I-RESULTS
> I-RESULTS
0.05 I-RESULTS
) I-RESULTS
. O

The O
most O
common O
side O
effect O
( O
grade O
III O
and O
IV O
) O
in O
the O
EOX B-DESC
group I-DESC
was O
reduction O
of O
white O
blood O
cell O
( O
WBC O
) O
, O
neutrophil O
, O
and O
platelet O
counts O
( O
10.53 O
% O
each O
) O
, O
while O
in O
the O
m O
- O
DCF O
group O
, O
the O
most O
adverse O
event O
was O
reduced O
neutrophil O
count O
( O
28.57 O
% O
) O
( O
Table O
3 O
) O
. O
Although O
there O
was O
no O
significant O
difference O
in O
terms O
of O
the O
side O
effects O
between O
the O
two O
groups O
, O
deep O
vein O
thrombosis O
( O
DVT O
) O
in O
the O
EOX B-DESC
group I-DESC
and O
neutropenic O
fever O
in O
the O
m B-DESC
- I-DESC
DCF I-DESC
group O
led O
to O
longer O
hospitals O
stays O
. O
All O
side O
effects O
were O
well O
treated O
with O
proper O
management O
. O
Overall O
, O
10 O
( O
47.61 O
% O
) O
patients O
from O
the O
m B-DESC
- I-DESC
DCF I-DESC
group O
and O
four O
( O
21.05 O
% O
) O
patients O
from O
the O
EOX B-DESC
group I-DESC
received O
supportive O
treatment O
during O
chemotherapy O
, O
although O
there O
was O
no O
significant O
difference O
between O
the O
groups O
( O
P= O
0.08 O
) O
( O
Table O
4 O
) O
. O

This O
study O
had O
several O
limitations O
, O
the O
most O
important O
of O
which O
is O
the O
small O
sample O
size O
. O
Other O
limitations O
of O
this O
study O
include O
the O
single B-STYPE
- I-STYPE
center I-STYPE
design I-STYPE
and O
lack O
of O
patient O
assessment O
regarding O
HER2 O
receptor O
status O
, O
nutritional O
status O
, O
and O
body O
mass O
index O
as O
prognostic O
factors O
. O
Considering O
these O
limitations O
, O
generalizability O
of O
our O
findings O
should O
be O
done O
with O
caution O
. O
We O
recommend O
further O
multi O
- O
center O
clinical O
trials O
with O
a O
larger O
sample O
size O
, O
longer O
follow O
- O
up O
, O
and O
quality O
of O
life O
assessment O
. O

The O
results O
of O
this O
study O
revealed O
that O
there O
is O
no O
significant O
difference O
between O
the O
m B-DESC
- I-DESC
DCF I-DESC
and O
EOX B-DESC
regimens I-DESC
regarding O
survival O
, O
PFS B-METRIC
, O
and O
side O
effects O
. O
However O
, O
considering O
the O
need O
for O
hospitalization O
due O
to O
continuous O
infusion O
of O
5-fluorouracil B-DESC
and O
lack O
of O
admission O
in O
the O
EOX B-DESC
group I-DESC
, O
this O
regimen O
seems O
to O
be O
more O
acceptable O
in O
patients O
who O
are O
unwilling O
to O
be O
hospitalized O
. O